Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Earnings

MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date

By The Northwire Desk — AI Analysis Feb 11, 2026 · 07:30 MRMD · 0.125 MariMed Inc.
MRMD · Price

Executive Summary

  • MariMed Inc. announced it will release its Q4 and full‑year 2025 financial results on March 11, 2026 after market close.
  • A management conference call to discuss the results is scheduled for March 12, 2026 at 8:00 a.m. EDT, with a live webcast and replay available on the Investor Relations website.

Key Details

  • Announcement made via GlobeNewswire from Norwood, Massachusetts.
  • Reporting date: March 11, 2026 (post‑market).
  • Conference call: March 12, 2026, 8:00 a.m. EDT; dial‑in details to be provided in the webcast invitation.
  • Webcast access: through MariMed’s Investor Relations site at “MariMed Q425 Earnings Webcast.”
  • Playback of the call will also be posted on the same website after the live event.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from MariMed Inc.

Jun 25, 2026 · 14:50

DEA registration submission marks a procedural step toward federal compliance, but execution risk and capital constraints remain the dominant narrative.

Regulatory May 13, 2026 · 17:00

Q1 2026 Earnings

Earnings Mar 11, 2026 · 17:05

MariMed Reports Fourth Quarter and Full Year 2025 Earnings

Earnings Mar 02, 2026 · 16:15

MariMed Extends Series B Preferred Stock Obligation Through 2031, Strengthening Capital Structure

Financings Jan 22, 2026 · 07:30

MariMed Launches Hemp-Derived THC Products Under its Vibations(TM) Brand in Rhode Island

Production / Operations Dec 18, 2025 · 13:52

MariMed Statement on Historic Rescheduling of Cannabis

Production / Operations